COSCIENS Biopharma Inc. Announces Leadership Change
COSCIENS Biopharma (TSX: CSCI / OTC: CSCIF) announced that Peter H. Puccetti, CFA, chairman of the board, has been appointed Interim Chief Executive Officer effective immediately following the departure of Anna Biehn on November 14, 2025. The board said the leadership change accompanies efforts to reduce costs, streamline the organization, and align resources with strategic priorities.
Management says Mr. Puccetti will continue driving the company’s strategic reorientation and focus on strengthening operational performance to create shareholder value during the transition.
COSCIENS Biopharma (TSX: CSCI / OTC: CSCIF) ha annunciato che Peter H. Puccetti, CFA, presidente del consiglio di amministrazione, è stato nominato CEO ad interim con effetto immediato a seguito della partenza di Anna Biehn il 14 novembre 2025. Il consiglio ha detto che il cambio di leadership accompagna gli sforzi per ridurre i costi, razionalizzare l'organizzazione e allineare le risorse alle priorità strategiche.
La direzione afferma che il sig. Puccetti continuerà a guidare la ridefinizione strategica dell'azienda e a concentrarsi sul rafforzamento delle prestazioni operative per creare valore per gli azionisti durante la fase di transizione.
COSCIENS Biopharma (TSX: CSCI / OTC: CSCIF) ha anunciado que Peter H. Puccetti, CFA, presidente de la junta, ha sido nombrado Director Ejecutivo Interino con efecto inmediato tras la salida de Anna Biehn el 14 de noviembre de 2025. La junta dijo que el cambio de liderazgo acompaña esfuerzos para reducir costos, simplificar la organización y alinear los recursos con las prioridades estratégicas.
La gestión afirma que el Sr. Puccetti continuará impulsando la reorientación estratégica de la empresa y se centrará en fortalecer el rendimiento operativo para crear valor para los accionistas durante la transición.
COSCIENS Biopharma (TSX: CSCI / OTC: CSCIF)는 이사회 의장인 Peter H. Puccetti, CFA가 Anna Biehn의 퇴임 직후인 2025년 11월 14일부로 임시 최고경영책임자(Interim Chief Executive Officer)로 임명되었음을 발표했다. 이사회는 이 리더십 변화가 비용 절감, 조직 간소화 및 전략적 우선순위에 맞춘 자원 배분 노력을 수반한다고 말했다.
경영진은 Puccetti 씨가 회사의 전략적 재구성을 추진하고 전환 기간 동안 주주 가치를 창출하기 위해 운영 성과를 강화하는 데 집중할 것이라고 전했다.
COSCIENS Biopharma (TSX: CSCI / OTC: CSCIF) a annoncé que Peter H. Puccetti, CFA, chairman du conseil d'administration, a été nommé Directeur Général Intérimaire avec effet immédiat à la suite du départ d'Anna Biehn le 14 novembre 2025. Le conseil a déclaré que ce changement de direction accompagne des efforts pour réduire les coûts, rationaliser l'organisation et aligner les ressources sur les priorités stratégiques.
La direction indique que M. Puccetti continuera à piloter la réorientation stratégique de l'entreprise et à se concentrer sur le renforcement de la performance opérationnelle afin de créer de la valeur pour les actionnaires pendant la période de transition.
COSCIENS Biopharma (TSX: CSCI / OTC: CSCIF) hat bekannt gegeben, dass Peter H. Puccetti, CFA, Vorsitzender des Vorstands, mit sofortiger Wirkung zum Interim Chief Executive Officer ernannt wurde, nach dem Weggang von Anna Biehn am 14. November 2025. Der Vorstand sagte, dass der Führungswechsel mit Bemühungen einhergeht, Kosten zu senken, die Organisation zu straffen und Ressourcen auf strategische Prioritäten auszurichten.
Die Geschäftsführung erklärte, dass Herr Puccetti die strategische Neuausrichtung des Unternehmens weiter vorantreiben und sich darauf konzentrieren werde, die operative Leistungsfähigkeit zu stärken, um während der Übergangsphase den Aktionärswert zu schaffen.
COSCIENS Biopharma (TSX: CSCI / OTC: CSCIF) أعلنت أن السيد Peter H. Puccetti, CFA، رئيس مجلس الإدارة، قد تم تعيينه رئيساً تنفيذياً مؤقتاً اعتباراً من الآن عقب مغادرة أنّا بيرن في 14 نوفمبر 2025. وقال المجلس إن تغيير القيادة يرافق جهود خفض التكاليف وتبسيط التنظيم وتوجيه الموارد نحو الأولويات الاستراتيجية.
وقالت الإدارة إن السيد Puccetti سيواصل قيادة إعادة توجيه الشركة الاستراتيجي والتركيز على تعزيز الأداء التشغيلي لخلق قيمة للمساهمين خلال فترة الانتقال.
- Immediate leadership continuity by promoting the board chair
- Explicit cost-reduction focus aligned with strategic priorities
- Chair has prior value-creation experience with similar businesses
- CEO resignation creates short-term leadership uncertainty
- No timeline provided for appointment of a permanent CEO
- No financial guidance or near-term operational targets disclosed
TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on natural ingredients and pharmaceutical solutions, announced today that Peter H. Puccetti, CFA, Chairman of the Company’s board of directors (the “Board”), has been appointed Interim Chief Executive Officer, effective immediately. Peter succeeds Anna Biehn, who has stepped down as Chief Executive Officer.
“As the Company continues its efforts to reduce costs and streamline its organizational structure while aligning resources with key strategic priorities, the Board has determined that now is the right time to transition leadership” said Robert Seager, Chair of the Human Resources, Nominating and Governance Committee. “Peter is already deeply involved in driving the strategic reorientation of the Company and has a proven track record of creating value with similarly situated businesses. We are confident that the Company will be well-served by Peter’s leadership at this critical juncture.”
Mr. Puccetti said, “In my expanded role as Chairman and Interim CEO, I plan on continuing to strengthen operational performance, while working to create the conditions necessary for driving shareholder value.” Mr. Puccetti continued, “On behalf of everyone at COSCIENS, I want to thank Anna for her professionalism, leadership and contributions. We wish her all the best in her future endeavors.”
About COSCIENS Biopharma Inc.
COSCIENS is a life science company with a diverse portfolio focused on the development of natural, plant-based active ingredients and engaged in the commercialization of pharmaceutical and diagnostic products. COSCIENS’ natural active ingredient business leverages the Company’s proprietary manufacturing and extraction technologies to develop Avenanthramides and Beta Glucan active ingredients currently used in leading skincare brands worldwide. COSCIENS’ lead pharmaceutical product Macimorelin (Macrilen; Ghryvelin), is the first and only U.S. Food and Drug Administration (“FDA”) and European Medicines Agency (“EMA”) approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
The Company’s common shares are listed on the Toronto Stock Exchange (“TSX”) under the symbol “CSCI”. The Company’s common shares were assigned the trading symbol “CSCIF” by FINRA’s Department of Market Operations for quoting and trading in the market for unlisted securities (i.e., the “over-the-counter market” or “OTC” market) in the United States as of September 4, 2025. For more information, please visit COSCIENS' website at www.cosciensbio.com.
Forward-Looking Statements
Certain statements in this news release, referred to herein as "forward-looking statements", constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and "forward-looking information" under the provisions of Canadian securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements. When used in this MD&A, words such as "anticipate", "assume", "believe", "could", "expect", "forecast", "future", "goal", "guidance", "intend", "likely", "may", "would" or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward-looking statements include such words. Forward-looking statements in this news release include, but are not limited to, statements relating to the expectations of the interim Chief Executive Officer.
These statements are based on current expectations and assumptions, including factors or assumptions factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from those expressed or implied by such forward-looking statements, including but not limited to the factors described in “Risks Relating to Us and Our Business” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2024. Given these risks, undue reliance should not be placed on these forward-looking statements, which apply only as of their dates. We disclaim any obligation to update any such risks or uncertainties or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.
Issuer Contact:
Peter H. Puccetti
Interim CEO and Chairman of the Board
pp@cosciensbio.com
Giuliano La Fratta
Chief Financial Officer
glafratta@cosciensbio.com
Investor Contact:
IR@cosciensbio.com
FAQ
Who is the interim CEO of COSCIENS Biopharma (CSCI) as of November 14, 2025?
Why did COSCIENS (CSCI) change leadership on November 14, 2025?
What did Interim CEO Peter Puccetti say about COSCIENS' priorities after his appointment?
Did COSCIENS (CSCI) name a permanent CEO on November 14, 2025?
How might the leadership change affect COSCIENS (CSCI) near term?
Where is COSCIENS Biopharma (CSCI) headquartered and how is the stock listed?
